This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Banks, R. E. Articles by Selby, P. J. Search for Related Content PubMed PubMed Citation Articles by Banks, R. E. Articles by Selby, P. J.

Genetic and Epigenetic Analysis of von Hippel-Lindau (VHL) Gene Alterations and Relationship with Clinical Variables in Sporadic Renal Cancer

¹ Cancer Research UK Clinical Centre, ² Department of Urology, and ³ Cancer Research UK Mutation Detection Facility, St. James's University Hospital; ⁴ Clinical Trials Research Unit, University of Leeds, Springfield Mount, Leeds; and ⁵ Cancer Research UK Renal Molecular Oncology Group, University of Birmingham, Edgbaston, United Kingdom

Requests for reprints: Rosamonde E. Banks, Cancer Research UK Clinical Centre, St. James's University Hospital, Beckett Street, Leeds LS9 7TF, United Kingdom. Phone: 44-113-206-4927; Fax: 44-113-242-9886; E-mail: r.banks{at}leeds.ac.uk.

Genetic and epigenetic changes in the von Hippel-Lindau (VHL) tumor suppressor gene are common in sporadic conventional renal cell carcinoma (cRCC). Further insight into the clinical significance of these changes may lead to increased biological understanding and identification of subgroups of patients differing prognostically or who may benefit from specific targeted treatments. We have comprehensively examined the VHL status in tissue samples from 115 patients undergoing nephrectomy, including 96 with sporadic cRCC. In patients with cRCC, loss of heterozygosity was found in 78.4%, mutation in 71%, and promoter methylation in 20.4% of samples. Multiplex ligation–dependent probe amplification identified intragenic copy number changes in several samples including two which were otherwise thought to be VHL-noninvolved. Overall, evidence of biallelic inactivation was found in 74.2% of patients with cRCC. Many of the mutations were novel and approximately two-thirds were potentially truncating. Examination of these and other published findings confirmed mutation hotspots affecting codons 117 and 164, and revealed a common region of mutation in codons 60 to 78. Gender-specific differences in methylation and mutation were seen, although not quite achieving statistical significance (P = 0.068 and 0.11), and a possible association between methylation and polymorphism was identified. No significant differences were seen between VHL subgroups with regard to clinicopathologic features including stage, grade, tumor size, cancer-free and overall survival, with the exception of a significant association between loss of heterozygosity and grade, although a possible trend for survival differences based on mutation location was apparent. (Cancer Res 2006; 66(4): 2000-11)

This article has been cited by other articles:

				P. Gergics, A. Patocs, M. Toth, P. Igaz, N. Szucs, I. Liko, F. Fazakas, I. Szabo, B. Kovacs, E. Glaz, et al. Germline VHL gene mutations in Hungarian families with von Hippel-Lindau disease and patients with apparently sporadic unilateral pheochromocytomas Eur. J. Endocrinol., September 1, 2009; 161(3): 495 - 502. [Abstract] [Full Text] [PDF]

				J. S.P. Yuen, E. Akkaya, Y. Wang, M. Takiguchi, S. Peak, M. Sullivan, A. S. Protheroe, and V. M. Macaulay Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer Mol. Cancer Ther., June 1, 2009; 8(6): 1448 - 1459. [Abstract] [Full Text] [PDF]

				V.-D. Luu, G. Boysen, K. Struckmann, S. Casagrande, A. von Teichman, P. J. Wild, T. Sulser, P. Schraml, and H. Moch Loss of VHL and Hypoxia Provokes PAX2 Up-Regulation in Clear Cell Renal Cell Carcinoma Clin. Cancer Res., May 15, 2009; 15(10): 3297 - 3304. [Abstract] [Full Text] [PDF]

				I. Wacker, M. Sachs, K. Knaup, M. Wiesener, J. Weiske, O. Huber, Z. Akcetin, and J. Behrens Key Role for Activin B in Cellular Transformation after Loss of the von Hippel-Lindau Tumor Suppressor Mol. Cell. Biol., April 1, 2009; 29(7): 1707 - 1718. [Abstract] [Full Text] [PDF]

				C.-Y. Ko, H.-C. Hsu, M.-R. Shen, W.-C. Chang, and J.-M. Wang Epigenetic Silencing of CCAAT/Enhancer-binding Protein {delta} Activity by YY1/Polycomb Group/DNA Methyltransferase Complex J. Biol. Chem., November 7, 2008; 283(45): 30919 - 30932. [Abstract] [Full Text] [PDF]

				M. L. Nickerson, E. Jaeger, Y. Shi, J. A. Durocher, S. Mahurkar, D. Zaridze, V. Matveev, V. Janout, H. Kollarova, V. Bencko, et al. Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors Clin. Cancer Res., August 1, 2008; 14(15): 4726 - 4734. [Abstract] [Full Text] [PDF]

				K. M. Smits, L. J. Schouten, B. A.C. van Dijk, C. A. Hulsbergen-van de Kaa, K. A.D. Wouters, E. Oosterwijk, M. van Engeland, and P. A. van den Brandt Genetic and Epigenetic Alterations in the von Hippel-Lindau Gene: the Influence on Renal Cancer Prognosis Clin. Cancer Res., February 1, 2008; 14(3): 782 - 787. [Abstract] [Full Text] [PDF]

				W. K. Rathmell, W. M. Stadler, and B. I. Rini Rational Therapeutic Choices and Strategies for Patients with Metastatic Renal Cancer ASCO Educational Book, January 1, 2008; 2008(1): 192 - 198. [Abstract] [Full Text] [PDF]

				W. Stadler Chromosomes, Hypoxia, Angiogenesis, and Trial Design: A Brief History of Renal Cancer Drug Development Clin. Cancer Res., March 15, 2007; 13(6): 1630 - 1633. [Full Text] [PDF]